JP2006501238A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006501238A5 JP2006501238A5 JP2004530464A JP2004530464A JP2006501238A5 JP 2006501238 A5 JP2006501238 A5 JP 2006501238A5 JP 2004530464 A JP2004530464 A JP 2004530464A JP 2004530464 A JP2004530464 A JP 2004530464A JP 2006501238 A5 JP2006501238 A5 JP 2006501238A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- hexyloxy
- carboxy
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 3
- ZJKZKKPIKDNHDM-UHFFFAOYSA-L calcium;6-(5-carboxylato-5-methylhexoxy)-2,2-dimethylhexanoate Chemical compound [Ca+2].[O-]C(=O)C(C)(C)CCCCOCCCCC(C)(C)C([O-])=O ZJKZKKPIKDNHDM-UHFFFAOYSA-L 0.000 claims 3
- 150000001721 carbon Chemical group 0.000 claims 3
- 229940111134 coxibs Drugs 0.000 claims 3
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 3
- 150000001983 dialkylethers Chemical class 0.000 claims 3
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 2
- 229960002004 valdecoxib Drugs 0.000 claims 2
- SDMBRCRVFFHJKR-UHFFFAOYSA-N 6-(5-carboxy-5-methylhexoxy)-2,2-dimethylhexanoic acid Chemical compound OC(=O)C(C)(C)CCCCOCCCCC(C)(C)C(O)=O SDMBRCRVFFHJKR-UHFFFAOYSA-N 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010007710 Cartilage injury Diseases 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000008407 joint function Effects 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 229960004662 parecoxib Drugs 0.000 claims 1
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 150000003536 tetrazoles Chemical class 0.000 claims 1
Claims (6)
ｎ及びｍは、独立に２〜９の整数であり；
Ｒ1、Ｒ2、Ｒ3、及びＲ4は、独立にＣ1〜Ｃ6アルキル、Ｃ2〜Ｃ6アルケニル、又はＣ2〜Ｃ6アルキニルであるか；又は
Ｒ1及びＲ2が、それらが結合している炭素原子と一緒に、又は、Ｒ3及びＲ4が、それらが結合している炭素原子と一緒になって、又は、Ｒ1及びＲ2が、それらが結合している炭素原子と一緒に、及び、Ｒ3及びＲ4が、それらが結合している炭素原子と一緒になって、３〜６の炭素を有する炭素環を形成することができ；
Ｙ1及びＹ2は、独立に、ＣＯＯＨ、ＣＨＯ、テトラゾール、又はＣＯＯＲ5であって、Ｒ5がＣ1〜Ｃ6アルキル、Ｃ2〜Ｃ6アルケニル、又はＣ2〜Ｃ6アルキニルであり；そして
該アルキル、アルケニル、及びアルキニル基は、ハロ、ヒドロキシ、Ｃ1〜Ｃ6アルコキシ、及びフェニルから選択される１又は２の基で置換されていてもよい。）
の置換ジアルキルエーテル又は薬学的に許容できるその塩を活性成分として含んでなる医薬組成物。 A pharmaceutical composition for preventing or treating osteoarthritis or rheumatoid arthritis, for preventing or treating cartilage damage, for reducing joint pain, or for improving joint function, formula I:
n and m are each independently an integer from 2 to 9;
R 1 , R 2 , R 3 , and R 4 are independently C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl; or R 1 and R 2 are Together with the carbon atom to which R is attached, or R 3 and R 4 together with the carbon atom to which they are attached, or R 1 and R 2 are the carbon to which they are attached. Together with the atoms and R 3 and R 4 together with the carbon atom to which they are attached can form a carbocycle having 3-6 carbons;
Y 1 and Y 2 are independently COOH, CHO, tetrazole, or COOR 5 , wherein R 5 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, or C 2 -C 6 alkynyl; and said alkyl, alkenyl, and alkynyl groups, halo, hydroxy, C 1 -C 6 alkoxy, and may be substituted with 1 or 2 groups selected from phenyl. )
A substituted dialkyl ether or a pharmaceutically acceptable salt thereof as an active ingredient.
ａ）６−（５−カルボキシ−５−メチル−ヘキシルオキシ）−２,２−ジメチルヘキサン酸・カルシウム塩；
ｂ）選択的ＣＯＸ−２阻害剤又は薬学的に許容できるその塩；
ｃ）薬学的に許容できる担体又は希釈剤
を含んでなる組成物。 A pharmaceutical composition comprising:
a) 6- (5-carboxy-5-methyl-hexyloxy) -2,2-dimethylhexanoic acid calcium salt;
b) a selective COX-2 inhibitor or a pharmaceutically acceptable salt thereof;
c) A composition comprising a pharmaceutically acceptable carrier or diluent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40525002P | 2002-08-22 | 2002-08-22 | |
| PCT/IB2003/003664 WO2004017952A1 (en) | 2002-08-22 | 2003-08-13 | Method of treating osteoarthritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006501238A JP2006501238A (en) | 2006-01-12 |
| JP2006501238A5 true JP2006501238A5 (en) | 2006-09-28 |
Family
ID=31946834
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004530464A Withdrawn JP2006501238A (en) | 2002-08-22 | 2003-08-13 | How to treat osteoarthritis |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1539127A1 (en) |
| JP (1) | JP2006501238A (en) |
| KR (1) | KR20050058454A (en) |
| CN (1) | CN1678297A (en) |
| AU (1) | AU2003255937A1 (en) |
| BR (1) | BR0313883A (en) |
| CA (1) | CA2494544A1 (en) |
| IL (1) | IL166600A0 (en) |
| MX (1) | MXPA05001254A (en) |
| PL (1) | PL375742A1 (en) |
| TW (1) | TW200410677A (en) |
| WO (1) | WO2004017952A1 (en) |
| ZA (1) | ZA200501133B (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004105801A1 (en) * | 2003-05-30 | 2004-12-09 | Warner-Lambert Company Llc | Animal model for the alleviation of pain using il-6 |
| WO2005002557A1 (en) * | 2003-07-03 | 2005-01-13 | Warner-Lambert Company Llc | Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof |
| US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
| DE102008000237A1 (en) | 2007-02-06 | 2008-08-07 | Basf Se | Mixtures, useful e.g. as an inhibitor or retarder for the stabilization of polymerizable compound, preferably swellable hydrogel-forming polymers, comprises a phenol imidazole derivative and a polymerizable compound |
| IL181577A0 (en) * | 2007-02-26 | 2007-07-04 | Jacob Bar Tana | Combination therapy composition and methods for the treatment of cardiovascular disorders and immune-related disorders |
| US8530420B2 (en) * | 2008-12-16 | 2013-09-10 | Kaohsiung Medical University | Treatment of arthritis with parathyroid hormone |
| TWI382841B (en) * | 2010-10-29 | 2013-01-21 | Univ China Medical | Pharmaceutical composition for inhibiting inflammation |
| KR20200054910A (en) * | 2017-04-18 | 2020-05-20 | 젬파이어 세러퓨틱스 인코포레이티드 | Gemcarbine, pharmaceutically acceptable salts, compositions and methods of use thereof |
| US20200253877A1 (en) * | 2018-10-18 | 2020-08-13 | Neurobo Pharmaceuticals, Inc. | Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor |
| CN114847223B (en) * | 2022-02-19 | 2023-11-07 | 昆明理工大学 | Method for establishing OA cynomolgus monkey model |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648387A (en) * | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| JP4750995B2 (en) * | 2000-01-25 | 2011-08-17 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | Calcium dicarboxylate ether, process for producing the same, and treatment of vascular diseases and diabetes using the same |
| US20030220374A1 (en) * | 2002-01-14 | 2003-11-27 | Pharmacia Corporation | Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors |
-
2003
- 2003-08-13 EP EP03792585A patent/EP1539127A1/en not_active Ceased
- 2003-08-13 JP JP2004530464A patent/JP2006501238A/en not_active Withdrawn
- 2003-08-13 AU AU2003255937A patent/AU2003255937A1/en not_active Abandoned
- 2003-08-13 PL PL03375742A patent/PL375742A1/en not_active Application Discontinuation
- 2003-08-13 CA CA002494544A patent/CA2494544A1/en not_active Abandoned
- 2003-08-13 MX MXPA05001254A patent/MXPA05001254A/en unknown
- 2003-08-13 KR KR1020057003022A patent/KR20050058454A/en not_active Application Discontinuation
- 2003-08-13 CN CNA038199513A patent/CN1678297A/en active Pending
- 2003-08-13 BR BR0313883-6A patent/BR0313883A/en not_active IP Right Cessation
- 2003-08-13 WO PCT/IB2003/003664 patent/WO2004017952A1/en not_active Application Discontinuation
- 2003-08-21 TW TW092123032A patent/TW200410677A/en unknown
-
2005
- 2005-01-31 IL IL16660005A patent/IL166600A0/en unknown
- 2005-02-08 ZA ZA200501133A patent/ZA200501133B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1111310T1 (en) | UNIONS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| JP2006501238A5 (en) | ||
| JP2007534702A5 (en) | ||
| JP2008540554A5 (en) | ||
| EP2266946A3 (en) | Compound For The Treatment Of Metabolic Disorders | |
| JP2009529540A5 (en) | ||
| ATE530066T1 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| HK1083460A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2005539054A5 (en) | ||
| JP2010534247A5 (en) | ||
| JP2004517813A5 (en) | ||
| UA95613C2 (en) | Compounds for the treatment of metabolic disorders | |
| JP2004518723A5 (en) | ||
| JP2011520906A5 (en) | ||
| JP2009530398A5 (en) | ||
| JP2004501940A5 (en) | ||
| ATE450496T1 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| ATE540675T1 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| JP2004525183A5 (en) | ||
| JP2005526773A5 (en) | ||
| JP2002522385A5 (en) | ||
| JP2004521150A5 (en) | ||
| JP2002522386A5 (en) | ||
| JP2005526149A5 (en) | ||
| JP2003532677A5 (en) |